Day: April 21, 2020

Aktia Bank PlcPress release21 April 2020 at 10.00 a.m.Aktia’s interim report for January–March will be published on Tuesday 5 May 2020 at 8.00 a.m.Aktia’s interim report for January–March 2020 will be published on Tuesday 5 May 2020 at 8.00 a.m. (EEST). The interim report is available at Aktia’s website www.aktia.com after the publication.Webcast from the results eventA live webcast will be sent from Aktia’s results event on Tuesday 5 May 2020 at 10.00 a.m. CEO Mikko Ayub and CFO Outi Henriksson will be presenting the results. The event will be held in English and can be seen live as a webcast or as a recording after the event at https://aktia.videosync.fi/2020-q1-results. The presentation material in English is available at Aktia’s website www.aktia.com before the results event.Aktia Bank PlcFurther information:Lotta...

Good morning,Please find below the press release issued today.Best regards,Florence LièvreGlobal PR Manager | Group Marketing & CommunicationsCapgemini Group | ParisTel.: +33 1 47 54 50 71Email : florence.lievre@capgemini.com_____________________Capgemini Press Contacts:                                                                             Efma Press Contact:Mary Sacchi (North America)                                                                                                Anna QuinnWE Communications for Capgemini                                                                   Tel.: +33 1 47 42 6771Tel.: +1 (212) 551 4818                                                                          E-mail: anna.quinn@efma.comE-mail: msacchi@we-worldwide.comBartu Sezer (EMEA)WE Communications for CapgeminiTel.: +44 020 7632...

Bonjour,Vous trouverez ci-après le communiqué de presse diffusé ce jour.Bien cordialement,Florence LièvreGlobal PR Manager | Group Marketing & CommunicationsCapgemini Group | ParisTel.: +33 1 47 54 50 71Email : florence.lievre@capgemini.com_____________________Contact Presse Capgemini :                                                                        Contact Presse Efma :Florence Lièvre                                                                                                                 Anna QuinnTél. : +33 (0)1 47 54 50 71                                                                       Tél. : +33 (0) 1 47 42 6771E-mail : florence.lievre@capgemini.com                                                 E-mail : anna.quinn@efma.comWorld FinTech Report 2020 : La collaboration avec les FinTechs plus que jamais essentielle...

Selskabsmeddelelse nr. 24/2020| 21. april 2020Udbuddet af op til 11.512.385 aktier (”Udbuddet”) i Danske Andelskassers Bank A/S (”Danske Andelskassers Bank”) er nu gennemført gennem en accelereret book-building. Der henvises til selskabsmeddelelse nr. 23/2020 af 20. april 2020.Som led i Udbuddet udsteder Danske Andelskassers Bank i alt 11.482.245 nye aktier til en tegningskurs på DKK 6,93 pr. aktie, hvilket giver Danske Andelskassers Bank et bruttoprovenu på DKK 79.571.958. Tegningsbeløbet er indbetalt.Ved fastsættelsen af tegningskursen er der taget højde for, at de nye aktier er udstedt uden ret til udbytte for 2019, der udbetales med DKK 0,56 pr. eksisterende aktie.KapitalforhøjelseKapitalforhøjelsen skete til markedskurs og består af 11.482.245 nye aktier á DKK 2. Danske Andelskassers Banks aktiekapital er derved forhøjet med nominelt...

VANCOUVER, British Columbia, April 21, 2020 (GLOBE NEWSWIRE) — Teck Resources Limited (TSX: TECK.A and TECK.B, NYSE: TECK) (“Teck”) reported adjusted EBITDA(1) (2) of $608 million for the first quarter of 2020 compared with $1.4 billion a year ago. Adjusted profit attributable to shareholders(1) (2) was $94 million ($0.17 per share) compared with $587 million ($1.03 per share) a year ago.“Our current focus is on managing the risks around COVID-19 and ensuring we have the necessary measures in place to safeguard our people and our local communities,” said Don Lindsay, President and CEO. “The pandemic has had a significant negative impact on the global economy and commodity markets and the outlook is uncertain. However, almost all of our sites are currently operating, with some at reduced production, and our steelmaking coal operations...

   2020 First-Quarter SalesPress release – Paris, April 21, 2020Resilience amid COVID-19Emmanuel Faber: Chairman and Chief Executive Officer statement“The first quarter of 2020 will long be remembered as the time of an unprecedented pandemic, which may change the way we live and do business for a long time ahead. In an effort to limit its immediate impact on the health of people, governments took lockdown actions that translated into waves of temporary freezes of both supply and demand in the economic equation. In this context, we focused on our continuity of business by ensuring maximum safety and security for our employees, both from a health and revenue guarantee standpoint. With the immediate and significant effects on demand shift, our quarterly sales grew +3.7% on a like-for-like basis, stronger than we had anticipated, with a China...

   Chiffre d’affaires du 1er trimestre 2020Communiqué de presse – Paris, le 21 avril 2020Résilience face au COVID-19Commentaire d’Emmanuel Faber, Président-Directeur GénéralLe premier trimestre de l’année 2020 restera longtemps dans les mémoires comme celui du démarrage d’une pandémie sans précédent, qui pourrait changer durablement notre manière de vivre et de travailler. Afin d’en limiter les impacts sur la santé des populations, les gouvernements ont adopté des mesures de confinement conduisant à des arrêts temporaires par vague à la fois de l’offre et la demande, modifiant ainsi les équations économiques. Dans ce contexte, nous nous sommes efforcés de maintenir la continuité de notre activité en nous assurant de la sécurité de nos salariés, en protégeant leur santé et en garantissant leurs revenus. Compte tenu des effets immédiats...

New long-term data from EXPAND show patients with SPMS continuously treated with Mayzent® (siponimod) experienced lower risk of disability progression and cognitive decline than patients who delayed Mayzent treatment1 Separate post-hoc analysis from EXPAND demonstrated Mayzent reduced cortical grey matter (cGM) and thalamic atrophy in patients with SPMS2, outcomes associated with long-term irreversible disability accumulation3 Mayzent is the first and only oral disease modifying therapy (DMT) studied and proven to delay disability progression in a broad range of SPMS patientsThe digital press release with multimedia content can be accessed here:   Basel, April 21, 2020 — Novartis announced today new Mayzent® (siponimod) data in the April supplemental issue of Neurology®, the medical journal of the American Academy of Neurology. The data...